載入中
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
前收盤價
US$3.16
−US$0.12 · -3.66%
盤後
US$3.16
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
日內區間
目前US$3.16
52週區間
目前US$3.16
盤中時間採用ET。市場資料可能有所延遲。
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
日內區間
目前US$3.16
52週區間
目前US$3.16
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.39億 USD | 1.35億 USD | 1.21億 USD | 1.06億 USD | 1.11億 USD |
| 銷貨成本 | 7393.8萬 USD | 5431.7萬 USD | 4814.4萬 USD | 6015.9萬 USD | 4578.4萬 USD |
| 毛利 | 6471.6萬 USD | 8111.9萬 USD | 7299.5萬 USD | 4536.3萬 USD | 6477.2萬 USD |
| 研究與開發 | 3592.2萬 USD | 3108.2萬 USD | 2606.4萬 USD | 2680.9萬 USD | 2838.3萬 USD |
| 銷售、一般及管理費用 | 1.39億 USD | 1.05億 USD | 9282.3萬 USD | 9185.1萬 USD | 9291萬 USD |
| 營業費用 | 1.75億 USD | 1.34億 USD | 1.19億 USD | 1.5億 USD | 1.21億 USD |
| 利息收入 | 856.7萬 USD | 1465.5萬 USD | 1583.9萬 USD | 513.1萬 USD | — |
| 利息支出 | — | — | — | — | 40.3萬 USD |
| 折舊和攤銷 | 1892.5萬 USD | 835.6萬 USD | 829萬 USD | 612.4萬 USD | 488萬 USD |
| 營業利益 | −1.1億 USD | −5261.6萬 USD | −4599.1萬 USD | −1.04億 USD | −5652.1萬 USD |
| 淨利 | −1.07億 USD | −3853.1萬 USD | −2835.4萬 USD | −9957.4萬 USD | −5554.8萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM373.68萬0.00%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI335.04萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF133.54萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB101.11萬0.01%108.2億 USD0.44%US$204.26-1.08%
Fidelity Enhanced Small Cap ETFFESM79.31萬0.01%64.1億 USD0.28%US$45.24-0.48%
Vanguard Russell 2000 ETFVTWO65.43萬0.00%180億 USD0.06%US$112.27-0.35%
U.S. Micro Cap Portfolio ETFDFMC52.17萬0.01%75.44億 USD0.43%US$57.70-0.20%
iShares Micro-Cap ETFIWC44.56萬0.03%13.17億 USD0.60%US$181.66-0.73%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOU.S. Micro Cap Portfolio ETFDFMCiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
